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Background: Chronic obstructive pulmonary disease (COPD) is an important public health issue in many countries
which is estimated to become the fifth cause of disability and the third cause of mortality in the world within 2020.
The objective of this study was to identify the clinical characteristics in the real clinical practice of a sample of
patients with COPD followed in a pulmonology clinic.
Methods: The initial sample contained 207 subjects with respiratory claims that searched for specialized treatment
and initiated regular monitoring between 2004 and 2009 in a private clinic localized in Cascavel, in the state of
Parana, Brazil. Demographic data (weight, height, body mass index - BMI), history of comorbidities, use of
respiratory and non respiratory drugs were also registered.
Results: The main cause related to the development of COPD was current or prior smoking (92.0%); the most
frequently reported symptom was dyspnea (95.0%), followed by cough (86.1%), wheezing (69.4%) and sputum
production (40.0%). During the follow up, 51 patients developed the need for oxygen therapy (28.3%). In 96
patients, there were periods of acute exacerbation, resulting in 37 hospitalizations. In addition to COPD, a significant
number of comorbidities were identified, being cardiovascular disease and neurological disorders the most
prevalent ones.
Conclusions: Based on the data collected, we could outline the profile of patients with COPD, showing
characteristics of an elderly population, with multiple comorbidities, suggesting a health related quality of life lower
than expected.
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Chronic obstructive pulmonary disease (COPD) is an
important public health issue in many countries which is
estimated to become the fifth cause of disability and the
third cause of mortality in the world within 2020 [1,2].
The prevalence of COPD in the world’s population is
considered to be around 1% concerning all age groups,
rising to 8-10% or more in individuals ≥ 40 years old
[3,4]. In Brazil, the PLATINO study (Latin American
Project for the Investigation of Pulmonary Obstruction)
identified a COPD prevalence of 15.8% in the population* Correspondence: oliveira.lvf@uninove.br
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distribution, and reproduction in any mediumliving in the metropolitan region of São Paulo, while
another epidemiological study demonstrated that the
prevalence of COPD is 9.1% when considering the popu-
lation between 40 and 70 years old [6].
Few studies have provided data about the epidemi-
ology of COPD [5,7-9] in the Latin America. Exposition
to respiratory risk factors also differ from one geograph-
ical area to another [10] and these factors, associated to
genetic predisposition and smoking, may be the reason
for the different features and severities of COPD patients
among the countries [11]. In recent years, epidemio-
logical studies have demonstrated a high and rising cost
of COPD around the world [3,4]. Moreover, the adher-
ence to treatment guidelines is low, especially in the less
developed countries [12-15].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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usually elderly and have, along with the respiratory dis-
ease, many other comorbidities [16,17]. There are thou-
sands of articles in the literature devoted specifically to
patients with COPD, however, as any clinical study has
specific inclusion and exclusion criteria, the current re-
searches are restricted to subgroups of COPD patients,
making a substantial number of other patients ineligible
primarily because of their comorbidities. In this way, it
is increasingly more difficult to delineate the true profile
of COPD patients in outpatient settings [10]. This paper
aims at characterizing these patients from the assess-
ment of demographic, clinical, and spirometric variables.Table 1 Baseline demographics of study population
(n = 180)
Variables Values
Age, years 67.7 ± 10.1
Sex (M:F), N (%) 142 (79%)/38 (21%)
Weight, Kg 69.1 ± 16.4
BMI, kg/m2 24.9 ± 5.2
Smokers (current and former), N (%) 166 (92.0%)
Smoking, pack/years 51 ± 14.9
Biomass exposure, N (%) 17 (9.4%)
Data are expressed as means ± SD unless otherwise indicated.Methods
In this cross-sectional study, the initial sample was com-
posed of 207 subjects with respiratory complaints who
looked for specialized pneumological care and started a
regular follow up between 2004 and 2009 in a private
clinic in Cascavel, in province of Parana, Brazil.
The diagnosis of COPD was confirmed by compatible
clinical presentation, presence of known risk factors as
smoking or exposition to biomass combustion (espe-
cially that from burned-over land) and observation of
post-bronchodilator FEV1/FVC ratio < 0.70 at spirom-
etry, according to Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) guidelines [2,16,17].
During the evaluation visit, all patients underwent de-
tailed anamnesis and physical examination, both conducted
by a pneumologist. It was investigated: the patient’s main
symptoms; degree of basal dyspnea according to the modi-
fied Medical Research Council scale (mMRC) [18]; causes
related to COPD development (smoking or exposition to
biomass combustion); previous or current tobacco con-
sumption; measurement of tobacco exposure in pack/years;
previous number of hospitalization events and exacerba-
tions; current use of long-term oxygen therapy (LTOT);
search for non-respiratory comorbidities and description of
all respiratory and non-respiratory medications currently
in use.
In the same day of clinical evaluation, study subjects’
weight and height were measured. These subjects
underwent pre and post-bronchodilator spirometry, fol-
lowing administration of albuterol 400 μg via MDI de-
vice, according to the American Thoracic Society (ATS)
guidelines for lung function [19]. Patients were previ-
ously informed by phone to discontinue bronchodilator
use before spirometric evaluation, so that short or long
acting β2-agonists and tiotropium were withheld for at
least 6, 12 and 24 h, respectively.
There was no restriction on the number or type of in-
haled or oral medications prescribed by the pneumologist
for controlling respiratory symptoms; they varied accordingto clinical and spirometric data, as well as each patient’s
income.
This study was approved by the Committee of Ethics
and Research of UniversidadeNove de Julho (UNINOVE–
Brazil) under Protocol 219561/2008. All patients signed
Informed Consent prior to participation and had the op-
tion to withdraw from the study at any time.
Statistical analysis
The data are presented in a descriptive mode. The vari-
ables, when indicated, are presented in absolute num-
bers, average, and standard deviation or as percentages.
Results
Our sample involved 180 patients with respiratory com-
plaints, with an average age of 67.7 ± 10.1 years. There
was an absolute prevalence of male gender (79%). The
main cause related to COPD development was previous
or current tobacco consumption (92%), including 9 cases
probably related to passive tobacco smoke exposure
(5%). The average tobacco smoke exposure was 51 ±
14.9 pack/years. Another less frequent cause was the ex-
posure to biomass combustion (wood-fired ovens and
burned-over land), identified in 17 patients (9.4%). The
average body-mass index (BMI) was 24.9 ± 5.2 kg/m2
with 45 patients (25%) presenting a BMI ≥ 21 kg/m2
(Table 1).
The most frequently reported symptom was dyspnea
(95%) and 72.4% of the patients referred to dyspnea
degree 3 or 4 according to the mMRC scale. The other
symptoms, sorted in decreasing frequency order, were
chronic cough (86.1%), wheezing (69.4%), and sputum
production (40%). The average post-bronchodilator
FEV1 was 44.8 ± 16.7% of predicted, with most patients
being classified into GOLD III (36.7%) and IV (20.5%)
stages. During the follow up, 51 patients evolved with
need for LTOT (28.3%); among these patients in 13
cases (25%), after the optimization of bronchodilator
treatment, there was discontinuation of oxygen supple-
mentation. Acute periods of exacerbation occurred in 96
subjects (53.3%), eventually amounting to 119 episodes
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the main clinical features of the evaluated patients.
Evaluating the clinical history of follow up cases, we
identified, along with COPD, a significant number of
comorbidities, being the most prevalent the cardiovascu-
lar and neurological diseases, observed, respectively, in
58% and 21% of the subjects (Figure 1). Hypertension
was the most common cardiovascular comorbidity, iden-
tified in 100 patients (55%). In 79 patients (43.9%) only a
non-respiratory comorbidity was diagnosed, while 39 pa-
tients (21.7%) had two comorbidities and 12 cases (6.7%)
presented three or more comorbidities. In face of it, 90
patients (43.4%) reported daily use of three medications
(including the respiratory ones), while 70 (33.8%) use
four medications and 47 (22.8%) use five or more medi-
cations. Table 3 displays the main classes of respiratory
and non-respiratory medications used by the partici-
pants in the sample.
In our study, the symptoms of COPD were more
frequently ameliorated by prescription of long-acting
β2-agonists (formoterol or salmeterol) combined to in-
haled corticosteroids (90%) as a maintenance treatment.
The tiotropium was prescribed to 31.7% of the patients,
especially in case of persistence of symptoms among pa-
tients already taking other classes of bronchodilators. As
relief medication, the most used drugs were short-acting
β2-agonists (albuterol or fenoterol) (88.9%). Another
interesting fact of our study concerned the analysis ofTable 2 Clinical and functional characteristics of
evaluated COPD patients (n = 180)
Dyspnea 171 (95%)
Dyspnea Degree 1 (mMRC) 16 (8.8%)
Dyspnea Degree 2 (mMRC) 25 (13.8%)
Dyspnea Degree 3 (mMRC) 92 (51.1%)
Dyspnea Degree 4 (mMRC) 38 (21.3%)
Chronic Cough 155 (86.1%)
Sputum Production 72 (40.0%)
Wheezing 125 (69.4%)
Post-bronchodilator Spirometry: Mean ± SD
FVC (L) 2.19 ± 0.99
FVC (% of predicted) 75.0 ± 15.0
FEV1(L) 1.17 ± 0.52
FEV1(% of predicted) 44.81 ± 16.7
FEV1/FVC (%) 57 ± 12
COPD stage: N (%)
GOLD I 14 (7.8%)
GOLD II 63 (35.0%)
GOLD III 66 (36.7%)
OLD IV 37 (20.5%)
Data are expressed as number (%) or means ± SD as appropriate.non-respiratory medications, with 86.1% of patients tak-
ing regularly antihypertensives and diuretics (86.1%),
for example. Table 3 displays the main respiratory and
non-respiratory medications regularly used in the stud-
ied sample.
There was no difference in the frequency of exacer-
bations, use of LTOT and comorbidities according to
gender. However, we observed a higher frequency of
comorbidities in patients >60 years old in comparison
to patients ≤60 years, and this finding achieved statis-
tical significance (p = 0.04).
Discussion
The profile of COPD patients of our study revealed that
they are: elderly, mainly men, usually in advanced stages
of the disease and presenting multiple comorbidities.
Smoking was related by 92% of patients, being probably
the most common factor associated with COPD devel-
opment in this study, what is in accordance to the avail-
able literature [2,5].
Higher age is compatible with the period between the
beginning of exposure (usually tobacco smoke) and the
development of COPD, as less aged patients reflect prob-
ably a higher genetic predisposition or even deficiency of
α1-antitrypsin [2,20]. The prevalence of male gender is
consistent with previous studies in literature, with one
study indicating the presence of 83% male individuals
among more than 10,000 patients followed up in a respira-
tory clinic in Spain [17,21]. This finding probably reflects
the higher prevalence of tobacco smoking and a higher ex-
posure to occupational activities such as biomass combus-
tion in male gender, which could explain the higher
incidence of COPD among men [10,22,23]. Because of
higher age, the presence of other non-respiratory comor-
bidities is more common in COPD patients; in our sample
we observed that 72.2% of the subjects had at least one
non-respiratory comorbidity, with cardiovascular diseases
(coronary insufficiency, heart failure and arrhythmia) be-
ing the most prevalent ones. In the multicentric EPOCA
(Enfermedad Pulmonar Obstructiva Crónica en Acción)
Project, which was also dedicated to the analysis of the
features of patients with COPD, the prevalence of
comorbidities varied considerably according to the evalu-
ated country, oscillating from 38.1% in Argentina to 63.4%
in Spain [17].
The main symptom reported by the population studied
was dyspnea (92%), reflex of the ventilatory limitation
observed in COPD. The EPOCA study found similar re-
sults, with dyspnea being reported by 97% of the pa-
tients, followed by chronic cough (79.6%) and sputum
production (70.5%) [17]. COPD stages II and III were
the most prevalent (71.7%); this probably may be
explained by delayed diagnosis (sub-diagnosis) at the
earlier stages, since many patients initially ascribe their
Figure 1 Comorbidities found in evaluated COPD patients.
Table 3 Use of respiratory and non-respiratory
medications among evaluated COPD patients (n = 180)
Non-respiratory medications N (%)
Antihypertensivesincluding diuretics 155 (86.1%)
Antidiabetics 26 (14.5%)





Arterial vasodilators 32 (17.7%)
Antiarrhythmics 35 (19.4%)
Hypolipidemic drugs 39 (21.6%)
Respiratory medications N (%)
Short-acting β2-agonists/Ipratropium 160 (88.9%)
Long-acting β2-agonists 14 (7.8%)




Inhaled corticosteroids 5 (2.8%)
Methilxantines 153 (85%)
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The PLATINO study identified that 85.7% of the 144
patients diagnosed with COPD in the metropolitan region
of Sao Paulo had never received this diagnosis in their
lives [24]. Moreover, the same study observed that, among
the patients previously diagnosed with COPD, 42.7% had
never been counseled to stop smoking and 82.3% were not
receiving the recommended pharmacologic treatment.
Regarding the use of medications for the respiratory
system, it is interesting to note that almost 60% of the
sample consisted of patients with stage III and IV of the
GOLD classification. Based on this finding, the high
prescription in our sample of patients of β2-agonists as-
sociated with long-term inhaled corticosteroids (97.8%)
and tiotropium (31.7%) is easily explicable.
Similarly, also the great use of methylxanthines among
patients (85%) can be explained. The GOLD guidelines
point out that inhaled bronchodilators, where available,
should be used as first-line treatment in COPD, rather
than oral bronchodilators, including methylxanthines.
However, the same guidelines emphasize that methyl-
xanthines can and should be considered in the treatment
of patients with COPD who remain symptomatic despite
the use of inhaled bronchodilators such as long-acting
β2-agonists association and tiotropium. Furthermore,
methylxanthines are low cost medications in Brazil,
compared to some classes of inhaled bronchodilators,
which may have contributed to the prescription above
expectations, according to recommendations from inter-
national guidelines.
The presence of LTOT in our sample is consistent
with previous studies, which reported that around 25%
of the followed subjects with COPD use LTOT
[13,21,25]. The high frequency of LTOT among these pa-
tients is justified by the loss in lung function and theventilation/perfusion mismatch, especially in the most
advanced phases of COPD [2,13].
We observed that almost one-third of the patients use
digitalic drugs daily; this is probably related to left ven-
tricle systolic dysfunction (LVSD) or even right failure
due to corpulmonale. A recent systematic review re-
vealed that the connection between COPD and LVSD is
probably much more prevalent than previously esti-
mated; superimposition rates between these two diseases
varied from 10% to 46%, especially during periods of
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was identified in 30 patients (16.6%), whereas the pres-
ence of LVSD was suggested in 20 patients (11.1%),
according to echocardiographic findings.
We also point out the high incidence of systemic
arterial hypertension (55%) in the evaluated subjects
(average age 67.7 years), since the prevalence of this
comorbidity (55%) increases linearly with age [26,27].
Besides that, many patients were using diuretics specif-
ically to ameliorate edema due to corpulmonale, or
angiotensin-converting enzyme (ACE) inhibitors due to
LSVD, thus explaining the use of antihypertensives (in-
cluding diuretics) in 155 patients (86.1%).
It is important to emphasize that almost 20% of the
patients took regularly antidepressants, a possible direct
reflex of patients’ compromised health status and quality
of life [23]. In this context, it is interesting to quote a re-
cent case–control study with more than 35,000 patients
with COPD which identified that the existence of COPD
itself doubles the risk of depression (OR 2.01, IC95%
1.45-2.78) [28]. Another finding of concern in our study
is the fact that the evaluated patients took many differ-
ent types of drugs, an average of at least four medi-
cations a day. This is clinically relevant, since COPD
patients are usually elderly patients, who frequently ex-
perience visual, hearing, and even cognitive deficits,
which could possibly reduce their compliance to these
medications, especially when they are not adequately
assisted by their relatives [29].
Conclusion
In conclusion, we observed that COPD patients followed
up are usually elderly, mainly men, and have multiple
comorbidities, especially cardiovascular diseases. There-
fore, a good design of the clinical profile of patients with
COPD may probably result in a more effective and individ-
ualized therapeutic approach. As limitation of our study
we can quote the fact we did not evaluate the impact of re-
spiratory and non-respiratory comorbidities in the quality
of life, as well as the compliance to medications in use.
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